Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naive Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial

Mason Malcolm D.; Clarke Noel W.; James Nicholas D.; Dearnaley David P.; Spears Melissa R.; Ritchie Alastair W. S.; Attard Gerhardt; Cross William; Jones Rob J.; Parker Christopher C.; Russell J. Martin; Thalmann George N.; Schiavone Francesca; Cassoly Estelle; Matheson David; Millman Robin; Rentsch Cyrill A.; Barber Jim; Gilson Clare; Ibrahim Azman; Logue John; Lydon Anna; Nikapota Ashok D.; OSullivan Joe M.; Porfiri Emilio; Protheroe Andrew; Srihari Narayanan Nair; Tsang David; Wagstaff John; Wallace Jan; Walmsley Catherine; Parmar Mahesh K. B.; Sydes Matthew R.

首页> 外文期刊>Journal of Clinical Oncology >Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naive Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial

【24h】

Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naive Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial

机译：添加细胞和没有唑酮酸的激素 - 野前列腺癌：来自适应性，多神，多级，平台，随机对照试验的长期存活结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2017年第14期|共15页
作者
Mason Malcolm D.; Clarke Noel W.; James Nicholas D.; Dearnaley David P.; Spears Melissa R.; Ritchie Alastair W. S.; Attard Gerhardt; Cross William; Jones Rob J.; Parker Christopher C.; Russell J. Martin; Thalmann George N.; Schiavone Francesca; Cassoly Estelle; Matheson David; Millman Robin; Rentsch Cyrill A.; Barber Jim; Gilson Clare; Ibrahim Azman; Logue John; Lydon Anna; Nikapota Ashok D.; OSullivan Joe M.; Porfiri Emilio; Protheroe Andrew; Srihari Narayanan Nair; Tsang David; Wagstaff John; Wallace Jan; Walmsley Catherine; Parmar Mahesh K. B.; Sydes Matthew R.;
展开▼
作者单位

Cardiff Univ Velindre Hosp Sch Med Cardiff Wales;

Christie &

Salford Royal NHS Fdn Trusts Salford Lancs England;

Inst Canc &

Genom Sci Birmingham W Midlands England;

Inst Canc Res London England;

UCL MRC Clin Trials Unit London W1N 4AL England;

UCL MRC Clin Trials Unit London W1N 4AL England;

Inst Canc Res London England;

Leeds Teaching Hosp NHS Trust Leeds W Yorkshire England;

Univ Glasgow Glasgow G12 8QQ Lanark Scotland;

Inst Canc Res London England;

Univ Glasgow Glasgow G12 8QQ Lanark Scotland;

Univ Hosp Bern Switzerland;

UCL MRC Clin Trials Unit London W1N 4AL England;

SAKK Coordinating Ctr Bern Switzerland;

UCL MRC Clin Trials Unit London W1N 4AL England;

UCL MRC Clin Trials Unit London W1N 4AL England;

Univ Hosp Basel Basel Switzerland;

Velindre Canc Ctr Cardiff Wales;

UCL MRC Clin Trials Unit London W1N 4AL England;

Clatterbridge Canc Ctr NHS Fdn Trust Wirral Merseyside England;

Christ Hosp Manchester Lancs England;

Torbay Dist Hosp Torquay England;

Sussex Canc Ctr Brighton E Sussex England;

Queens Univ Ctr Canc Res &

Cell Biol Belfast Antrim North Ireland;

Univ Birmingham Sch Med Birmingham B15 2TT W Midlands England;

Churchill Hosp Oxford England;

Shrewsbury &

Telford Hosp NHS Trust Shrewsbury Salop England;

Southend Hosp Southend On Sea England;

South West Wales Canc Inst Swansea W Glam Wales;

Beatson West Scotland Canc Ctr Glasgow Lanark Scotland;

Royal Preston Hosp Preston Lancs England;

UCL MRC Clin Trials Unit London W1N 4AL England;

UCL MRC Clin Trials Unit London W1N 4AL England;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献

1. Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naive Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial [J] . Mason Malcolm D., Clarke Noel W., James Nicholas D., Journal of Clinical Oncology . 2017,第14期

机译：添加细胞和没有唑酮酸的激素 - 野前列腺癌：来自适应性，多神，多级，平台，随机对照试验的长期存活结果
2. Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial [J] . Taneja Samir S. The Journal of Urology . 2016,第4期

机译：Re：加入多西紫杉醇，唑醇，或两种前列腺癌中的一线长期激素治疗：自适应，多神，多级，平台随机对照试验的生存结果
3. Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial [J] . Taneja Samir S. The Journal of Urology . 2016,第4期

机译：回复：多西他赛，唑来膦酸或两者都添加到前列腺癌的一线长期激素治疗中（STAMPEDE）：自适应多臂多阶段平台随机对照试验的生存结果
4. Randomized controlled trial comparing the effects of Nd:YAG prostate ablation with or without KTP laser bladder neck incision [C] . Stephen Langley, M.D., Southmead Hospital, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems VII . 1997

机译：随机对照试验比较Nd：YAG前列腺消融术与无KTP激光膀胱颈切口的效果
5. Evaluation of a randomized clinical trial of a psychoeducational intervention on long-term quality of life, negative affect, progression and survival in head and neck cancer patients. [D] . Trevino, Lara A. 2011

机译：心理教育干预对头颈部癌症患者的长期生活质量，负面影响，进展和生存的随机临床试验评估。
6. Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive Multiarm Multistage Platform Randomized Controlled Trial [O] . Malcolm D. Mason, Noel W. Clarke, Nicholas D. James, -1

机译：含或不含唑来膦酸的塞来昔布用于未经激素治疗的前列腺癌：自适应多臂多阶段平台随机对照试验的长期生存结果
7. Adding celecoxib with or without Zoledronic acid for hormone-naive prostate cancer: Long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial [O] . Mason, Malcolm D., Clarke, Noel W., James, Nicholas D., 2017

机译：在无激素的前列腺癌中加入含或不含唑来膦酸的塞来昔布：长期生存来自一项自适应，多臂，多阶段，平台，随机对照试验

Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naive Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial

摘要

著录项

相似文献

相关主题

期刊订阅